Gujarat Themis Biosyn Limited (NSE:GUJTHEM)
371.85
-19.10 (-4.89%)
At close: Aug 1, 2025, 3:30 PM IST
Satixfy Communications Revenue
In the fiscal year ending March 31, 2025, Gujarat Themis Biosyn had annual revenue of 1.51B INR, down -11.20%. Gujarat Themis Biosyn had revenue of 377.36M in the quarter ending March 31, 2025, a decrease of -9.55%.
Revenue
1.51B
Revenue Growth
-11.20%
P/S Ratio
27.45
Revenue / Employee
9.28M
Employees
159
Market Cap
40.52B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Mar 31, 2025 | 1.51B | -190.22M | -11.20% |
Mar 31, 2024 | 1.70B | 214.37M | 14.45% |
Mar 31, 2023 | 1.48B | 335.31M | 29.19% |
Mar 31, 2022 | 1.15B | 242.91M | 26.82% |
Mar 31, 2021 | 905.63M | 54.38M | 6.39% |
Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Sun Pharmaceutical Industries | 537.09B |
Divi's Laboratories | 93.60B |
Cipla | 274.80B |
Apollo Hospitals Enterprise | 217.94B |
Mankind Pharma | 128.90B |
Zydus Lifesciences | 232.42B |
Aurobindo Pharma | 317.24B |
Fortis Healthcare | 77.86B |